Mr. Ravenscroft has nearly 30 years of experience in the health care industry spanning senior product development and commer cial management roles in North America, Europe and Asia.
Most recently, he served as President of Bristol-Myers Squibb's Medical Imaging Business. He was also Vice President of Bristol-Myers Squibb's Global Virology Franchise. Mr. Ravenscroft has held executive and senior positions with DuPont Pharmaceutica l's Global HIV Business and GlaxoWellcome.
Mr. Ravenscroft holds a master's degree in Information Science from City University in the United Kingdom and a bachelor' s degree in Applied Biology from North East London University.
David Wetherell is a venture capitalist and former entrepreneur. His career began in software development in a variety of industries. The first software company he started, Softrend, Inc., developed the first software allowing PCs to access and download data from corporate mainframes, and one of the first integrated office software tool suites for desktop computers. He later led a leveraged buyout of a direct marketing company, College Marketing Group, and transformed it into CMGI. Since taking over the company, sales rose from $3M to over $1B annually. There, he started numerous Internet companies and the first venture capital firm for the Internet, @Ventures, which was responsible for the first investments in a number of key early companies in the Internet, including Lycos, GeoCities, Half.com (a large part of eBay), Vicinity (now, Microsoft's mapping technology), PlanetAll (part of Amazon.com), WebCT, and MyFamily.com (also known as Ancestry.com).
Today, he is chairman of CMGI, which has directed its venture capital efforts to clean energy technologies, and owns ModusLink, the largest supply chain management company in the world serving the high tech industry. In addition, Mr. Wetherell has personal venture investments in real estate, private aviation, and biotech. He started Greenwich Biotech Ventures, a venture capital company for the biotech industry in 2005. Mr. Wetherell has received numerous awards, including Ernst and Young's New England Entrepreneur of the Year, in 2000. He obtained his BA in Mathematics from Ohio Wesleyan University and an honorary doctorate from Bryant College.
Boro Dropulic is the Founder of Lentigen and serves as its President and Chief Scientific Officer. Dr. Dropulic is one of the leading experts in Lentiviral Vector technology. He is a member of the Infectious Diseases and Industrial Liaisons Committees for the American Society of Gene Therapy and a member of the Editorial Board of the journal Human Gene Therapy.
Prior to founding Lentigen, he was Founder and Chief Scientific Officer of VIRxSYS where he successfully led a multidisciplinary team to initiate and complete the first ever Lentiviral Vector clinical trial in humans. Prior to founding VIRxSYS, Dr Dropulic was an Instructor and then Adjunct Assistant Professor at Johns Hopkins University School of Medicine in Baltimore, Maryland, where he was the first to develop a HIV-based vector targeted to inhibit the replication of the HIV/AIDS virus.
Dr. Dropulic was a Fogarty Fellow at the National Institutes of Health where he worked on developing transgenic animals using embryonic stem cell technology, understanding molecular aspects of HIV replication and gene therapy for HIV/AIDS. He obtained his Ph.D. from the University of Western Australia focusing upon how viruses cause disease in the body. Dr Dropulic received his B.Sc. (Hons.) from the University of Western Australia and a MBA from The Johns Hopkins University.
Douglas Lind is a Managing Partner of Accendx Management, LLC. He was senior biotechnology equity research analyst at Morgan Stanley from 1997 through 2002 and at PaineWebber from 1995 to 1997. Previously, he was Managing Director of Lind & Co., a Boston-based biotechnology investment research firm serving institutional clients, which he founded in 1991. He is a former Tufts University Clinical Fellow in Medicine and a past member of the American Medical Association Council on Ethical and Judicial Affairs. During his tenure on the Council, he worked extensively on problems of resource allocation in health care. He has served on numerous national health policy bodies, including the Health Policy Agenda for the American People and the American Medical Association Task Force on Physician Manpower.
Dr. Lind is a graduate of the University of Iowa College of Medicine, 1987. From 1990 to 1992, he was a practicing physician in Brookline, Massachusetts. He served as an attending physician at St. Elizabeth's Hospital in Boston, a major teaching affiliate of Tufts University School of Medicine, where he completed his residency in Internal Medicine.
Jack McMullen is the Managing Principal of Cambridge Meridian Group, a strategy-consulting firm that serves Fortune 500 and technology-based companies. Mr. McMullen previously taught business strategy at Harvard Law School. He serves, or has served, on the Boards of three NASDAQ listed technology companies as well as 12 other privately funded, chiefly technology-oriented companies. From 1993 to 1997 he was an informal advisor to Senator Bradley (NJ). In 2004 he was the Republican nominee for the United States Senate from Vermont.
He is a Navy veteran who served on the staff of Admiral Rickover overseeing the retrofit of advanced technology reactors into the Navy's nuclear fleet. Mr. McMullen is a Phi Beta Kappa graduate of Columbia University in Applied Physics and Engineering and received a JD with Honors from Harvard Law School and an MBA with High Distinction from Harvard Business School, where he was elected a First Year Baker Scholar.
Bob Breyer has been a director of Alkermes since July 1994. He served as the President of Alkermes from July 1994 until his retirement in December 2001 and Chief Operating Officer from July 1994 to February 2001. Mr. Breyer is currently a part-time employee of Alkermes. From August 1991 to December 1993, Mr. Breyer was President and General Manager of Eli Lilly Italy, a subsidiary of Eli Lilly and Company. From September 1987 to August 1991, he was Senior Vice President, Marketing and Sales of IVAC Corporation, a medical device company and a subsidiary of Eli Lilly and Company. Mr. Breyer graduated from North Dakota State University in 1966 with a BS degree in pharmacy.
Barrie Carter has been Executive Vice President and Chief Scientific Officer of Targeted Genetics Corporation since 1992. From 1970 to 1992, he was at the US National Institutes of Health (NIH). From 1982 to 1992 he was Chief of the Laboratory of Molecular and Cellular Biology at the National Institute for Diabetes and Digestive and Kidney Diseases, NIH. Prior to joining the NIH, he was a post-doctoral fellow at the Imperial Cancer Research Fund Laboratories in London, England. He received his B.Sc. with First Class Honors from the University of Otago, Dunedin, New Zealand in 1966 and his Ph.D. in the Biochemistry Department of the University of Otago Medical School in 1969. Dr. Carter's long-term research interests are in the molecular biology of viruses, development of AAV vectors, gene therapy and the development of therapeutics.
Dr. Carter serves on the editorial boards of Human Gene Therapy and Virology and is an Associate Editor of Molecular Therapy. From 1995-2000 he was an Affiliate Professor of Medicine at the University of Washington Medical School. Dr. Carter has served on a variety of government, scientific, and academic advisory bodies. He currently serves on the External Advisory Committee of the University of Washington School of Public Health and Community Medicine, the Keystone Symposia Scientific Advisory Board, and the Board of Directors of the American Society of Gene Therapy. He has previously served on the Advisory Committee to the Director, NIH and the Scientific Review Committee for Intramural Research, CBER at the US FDA.
